Hollings Home  
 
Elizabeth Garrett-Mayer, PhD
Professor of Public Health Sciences
College of Medicine
MUSC

Email: garrettm@musc.edu
 
       Print This Page
       
 
 


 

Elizabeth Garrett-Mayer, PhD

Return to Search Page  

Research Interest:

My research activities focus on clinical trials. A large fraction of my time is spent collaborating with clinical oncologists designing and analyzing studies. In designing a clinical trial, I determine the most efficient way to answer the clinical question of interest, including how many patients should be studied, and how the trial will be conducted. The analysis consists of applying statistical methods to determine if, for example, the new treatment helped patients survive longer than they would have on another treatment. I also work on laboratory-based studies, including the exploration of the relationship between methylation markers and cancer incidence and progression, and gene expression microarray studies. There are numerous types of trials and studies within the Cancer Center and so the analytic methods that I use and the scientific questions I address are quite varied. My methodologic research relates closely to my applied interests. My primary statistical research areas of interest are in early phase studies. Specifically, I work on methods for finding efficient dose escalation designs and on new trial designs that allow early stopping when the primary outcome of interest is time to disease progression.

Positions:
Director, Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina

Selected Publications:

1.Sobolesky PM, Halushka PV, Garrett-Mayer E, Smith MT, Moussa O. Regulation of the Tumor Suppressor FOXO3 by the Thromboxane-A2 Receptors in Urothelial Cancer. PLoS One. .9(9):e107530, 2014. PMCID: PMC4159332
View in: PubMed

2.Kesarwani P, Al-Khami AA, Scurti GM, Thyagarajan K, Kaur N, Husain S, Fang Q, Naga OS, Simms P, Beeson G, Voelkel-Johnson C, Garrett-Mayer E, Beeson C, Nishimura MI, Mehrotra S. Promoting Thiol Expression Increases The Durability of Antitumor T cell Functions. Cancer Res. ., 2014.
View in: PubMed

3.Kummetha Venkata J, An N, Stuart R, Costa LJ, Cai H, Coker W, Song JH, Gibbs K, Matson T, Garrett-Mayer E, Wan Z, Ogretmen B, Smith C, Kang Y. Inhibition of sphingosine kinase 2 down-regulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood. ., 2014. PMCID: PMC4168346
View in: PubMed

4.Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA. A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer. Cancer Immunol Res. ., 2014.
View in: PubMed

5.Turner-Ivey B, Guest ST, Irish JC, Kappler CS, Garrett-Mayer E, Wilson RC, Ethier SP. KAT6A, a Chromatin Modifier from the 8p11-p12 Amplicon is a Candidate Oncogene in Luminal Breast Cancer. Neoplasia. .16(8):644-55, 2014.
View in: PubMed

6.Eby JM, Kang HK, Klarquist J, Chatterjee S, Mosenson JA, Nishimura MI, Garrett-Mayer E, Longley BJ, Engelhard VH, Mehrotra S, Le Poole IC. Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation. Pigment Cell Melanoma Res. ., 2014.
View in: PubMed

7.Mathew AR, Wahlquist AE, Garrett-Mayer E, Gray KM, Saladin ME, Carpenter MJ. Affective motives for smoking among early stage smokers. Nicotine Tob Res. .16(10):1387-93, 2014.
View in: PubMed

8.Opfermann KJ, Wahlquist AE, Garrett-Mayer E, Shridhar R, Cannick L, Marshall DT. Adjuvant Radiotherapy and Lymph Node Status for Pancreatic Cancer: Results of a Study From the Surveillance, Epidemiology, and End Results (SEER) Registry Data. Am J Clin Oncol. .37(2):112-6, 2014. PMCID: PMC3594531
View in: PubMed

9.American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. .32(12):1277-80, 2014.
View in: PubMed

10.Esnaola NF, Chaudhary UB, O'Brien P, Garrett-Mayer E, Camp ER, Thomas MB, Cole DJ, Montero AJ, Hoffman BJ, Romagnuolo J, Orwat KP, Marshall DT. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. .88(4):837-44, 2014. PMCID: PMC4120643
View in: PubMed

11.Grass GD, Cooper SL, Armeson K, Garrett-Mayer E, Sharma A. Cervical esophageal cancer: A population-based study. Head Neck. ., 2014.
View in: PubMed

12.Gosnell H, Kasman LM, Potta T, Vu L, Garrett-Mayer E, Rege K, Voelkel-Johnson C. Polymer-enhanced delivery increases adenoviral gene expression in an orthotopic model of bladder cancer. J Control Release. .176:35-43, 2013. PMCID: PMC3952388
View in: PubMed

13.Rossmann C, Garrett-Mayer E, Rattay F, Haemmerich D. Dynamics of tissue shrinkage during ablative temperature exposures. Physiol Meas. .35(1):55-67, 2013. PMCID: PMC3924587
View in: PubMed

14.Morales C, Rachidi S, Hong F, Sun S, Ouyang X, Wallace C, Zhang Y, Garret-Mayer E, Wu J, Liu B, Li Z. Immune chaperone gp96 drives the contributions of macrophages to inflammatory colon tumorigenesis. Cancer Res. .74(2):446-59, 2013. PMCID: PMC4002507
View in: PubMed

15.Nasarre P, Gemmill RM, Potiron VA, Roche J, Lu X, Barón AE, Korch C, Garrett-Mayer E, Lagana A, Howe PH, Drabkin HA. Neuropilin-2 Is upregulated in lung cancer cells during TGF-ß1-induced epithelial-mesenchymal transition. Cancer Res. .73(23):7111-21, 2013. PMCID: PMC3926507
View in: PubMed

16.Rudek MA, Connolly RM, Hoskins JM, Garrett-Mayer E, Jeter SC, Armstrong DK, Fetting JH, Stearns V, Wright LA, Zhao M, Watkins SP, McLeod HL, Davidson NE, Wolff AC. Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat. .139(1):135-43, 2013. PMCID: PMC3673300
View in: PubMed

17.Mosenson JA, Zloza A, Nieland JD, Garrett-Mayer E, Eby JM, Huelsmann EJ, Kumar P, Denman CJ, Lacek AT, Kohlhapp FJ, Alamiri A, Hughes T, Bines SD, Kaufman HL, Overbeck A, Mehrotra S, Hernandez C, Nishimura MI, Guevara-Patino JA, Le Poole IC. Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med. .5(174):174ra28, 2013. PMCID: PMC3912753
View in: PubMed

18.Hollis BW, Marshall DT, Savage SJ, Garrett-Mayer E, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation, low-risk prostate cancer, and health disparities. J Steroid Biochem Mol Biol. .136:233-7, 2012.
View in: PubMed

19.Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, Senkal CE, Garrett-Mayer E, De Palma RM, Fedarovich D, Liu A, Habib AA, Stahelin RV, Perrotti D, Ogretmen B. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. .5(1):105-21, 2012. PMCID: PMC3569657
View in: PubMed

20.Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M. Stromal cell-derived factor 1a mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia. .14(8):690-701, 2012. PMCID: PMC3432475
View in: PubMed

21.Mehrotra S, Al-Khami AA, Klarquist J, Husain S, Naga O, Eby JM, Murali AK, Lyons GE, Li M, Spivey ND, Norell H, Martins da Palma T, Onicescu G, Diaz-Montero CM, Garrett-Mayer E, Cole DJ, Le Poole IC, Nishimura MI. A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol. .189(4):1627-38, 2012. PMCID: PMC3674773
View in: PubMed

22.Garrett-Mayer E, Wagner CL, Hollis BW, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation (4000 IU/d for 1 y) eliminates differences in circulating 25-hydroxyvitamin D between African American and white men. Am J Clin Nutr. .96(2):332-6, 2012.
View in: PubMed

23.Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Smith BD, Greer JM, Drye DM, Mackey K, Dorcy KS, Gore SD, Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showel MM, Othus M, Doyle LA, Wright JJ, Pagel JM. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica. .97(11):1736-42, 2012. PMCID: PMC3487449
View in: PubMed

24.Hudspeth MP, Heath TS, Chiuzan C, Garrett-Mayer E, Nista E, Burton L, Ragucci D. Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT. Bone Marrow Transplant. .48(1):46-9, 2012.
View in: PubMed

25.Van Meter EM, Garrett-Mayer E, Bandyopadhyay D. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method. Clin Trials. .9(3):303-13, 2012.
View in: PubMed

26.Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, Horst RL, Ambrose LH, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. .97(7):2315-24, 2012. PMCID: PMC3387395
View in: PubMed

27.Taylor R, Opfermann K, Jones BD, Terwilliger LE, McDonald DG, Ashenafi MS, Garrett-Meyer E, Marshall DT. Comparison of radiation treatment delivery for pancreatic cancer: Linac intensity-modulated radiotherapy versus helical tomotherapy. J Med Imaging Radiat Oncol. .56(3):332-7, 2012.
View in: PubMed

28.Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, Hassan MM, Hassabo HM, Iwasaki M, Deaton FL, Abbruzzese JL, Thomas MB. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology. .82(2):67-74, 2012.
View in: PubMed

29.Logan SL, Nicholas JS, Carpenter LA, King LB, Garrett-Mayer E, Charles JM. High prescription drug use and associated costs among Medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance network. Ann Epidemiol. .22(1):1-8, 2012. PMCID: PMC3240812
View in: PubMed

30.Ford M, Wahlquist A, Blake R, Green C, Streets J, Fuller E, Johnson E, Jefferson M, Etheredge J, Varner H, Johnson S, Glover S, Turner D, Garrett-Mayer E. Assessing an intervention to improve clinical trial perceptions among predominately African-American communities in South Carolina. Prog Community Health Partnersh. .6(3):249-63, 2012. PMCID: PMC4180673
View in: PubMed

31.Curran JN, Garrett-Mayer E, Carpenter MJ, Ford ME, Silvestri GA, Lackland DT, Alberg AJ. Cigarette smoking and the risk of dying from tobacco-related malignancies by race. Anticancer Res. .31(11):3891-5, 2011.
View in: PubMed

32.Tanner NT, Watson P, Boylan A, Memoli JS, Pastis N, Taylor K, Garrett-Mayer E, Silvestri GA. Utilizing endobronchial ultrasound with fine-needle aspiration to obtain tissue for molecular analysis: a single-center experience. J Bronchology Interv Pulmonol. .18(4):317-21, 2011.
View in: PubMed

33.Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, Tarpinian KS, Powers PP, Wright LA, Donehower MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Garrett-Mayer E, Skaar TC, Davidson NE, Stearns V. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res (Phila). .4(12):1993-2001, 2011. PMCID: PMC3700336
View in: PubMed

34.Saddoughi SA, Garrett-Mayer E, Chaudhary U, O'Brien PE, Afrin LB, Day TA, Gillespie MB, Sharma AK, Wilhoit CS, Bostick R, Senkal CE, Hannun YA, Bielawski J, Simon GR, Shirai K, Ogretmen B. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. .17(18):6097-105, 2011. PMCID: PMC3176980
View in: PubMed

35.Kraft AS, Garrett-Mayer E, Wahlquist AE, Golshayan A, Chen CS, Butler W, Bearden J, Lilly M. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. .12(2):119-24, 2011.
View in: PubMed

36.Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, Garrett-Mayer E, Montero AJ, Bronte V, Mandruzzato S. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood. .118(8):2254-65, 2011. PMCID: PMC3709641
View in: PubMed

37.Memoli JS, El-Bayoumi E, Pastis NJ, Tanner NT, Gomez M, Huggins JT, Onicescu G, Garrett-Mayer E, Armeson K, Taylor KK, Silvestri GA. Using endobronchial ultrasound features to predict lymph node metastasis in patients with lung cancer. Chest. .140(6):1550-6, 2011. PMCID: PMC3231960
View in: PubMed

38.Kearney PL, Watkins JM, Shirai K, Wahlquist AE, Fortney JA, Garrett-Mayer E, Gillespie MB, Sharma AK. Salvage Resection for Isolated Local and/or Regional Failure of Head/Neck Cancer Following Definitive Concurrent Chemoradiotherapy Case Series and Review of the Literature. Mcgill J Med. .13(2):29, 2011. PMCID: PMC3277417
View in: PubMed

39.Ryan KK, Garrett-Mayer E, Alberg AJ, Cartmell KB, Carpenter MJ. Predictors of cessation pharmacotherapy use among black and non-Hispanic white smokers. Nicotine Tob Res. .13(8):646-52, 2011. PMCID: PMC3150684
View in: PubMed

40.Gopal U, Bohonowych JE, Lema-Tome C, Liu A, Garrett-Mayer E, Wang B, Isaacs JS. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLoS One. .6(3):e17649, 2011. PMCID: PMC3050925
View in: PubMed

41.Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, Wolff AC. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat. .127(1):153-62, 2011. PMCID: PMC3111459
View in: PubMed

42.Van Meter EM, Garrett-Mayer E, Bandyopadhyay D. Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading. Stat Med. .30(17):2070-80, 2011. PMCID: PMC3117067
View in: PubMed

43.Leoutsakos JM, Bandeen-Roche K, Garrett-Mayer E, Zandi PP. Incorporating scientific knowledge into phenotype development: penalized latent class regression. Stat Med. .30(7):784-98, 2010. PMCID: PMC3574638
View in: PubMed

44.Watkins JM, Wahlquist AE, Zauls AJ, Fields EC, Garrett-Mayer E, Aguero EG, Silvestri GA, Sharma AK. High-dose fractionated radiotherapy to 80 Gy for stage I-II medically inoperable non-small-cell lung cancer. J Med Imaging Radiat Oncol. .54(6):554-61, 2010.
View in: PubMed

45.El-Zawahry AM, Clarke HS, Eskridge MR, Rieter W, Onicescu G, Garrett-Mayer E, Gordon LL, Keane TE. Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate. Urology. .76(5):1162-7, 2010.
View in: PubMed

46.Scharpf RB, Iacobuzio-Donahue CA, Cope L, Ruczinski I, Garrett-Mayer E, Lakkur S, Campagna D, Parmigiani G. Cross-platform Comparison of Two Pancreatic Cancer Phenotypes. Cancer Inform. .9:257-64, 2010. PMCID: PMC2978933
View in: PubMed

47.Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett. .300(1):66-78, 2010. PMCID: PMC3337721
View in: PubMed

48.Zauls AJ, Watkins JM, Wahlquist AE, Brackett NC, Aguero EG, Baker MK, Jenrette JM, Garrett-Mayer E, Harper JL. Outcomes in women treated with MammoSite brachytherapy or whole breast irradiation stratified by ASTRO Accelerated Partial Breast Irradiation Consensus Statement Groups. Int J Radiat Oncol Biol Phys. .82(1):21-9, 2010.
View in: PubMed

49.Watkins JM, Wahlquist AE, Zauls AJ, Shirai K, Garrett-Mayer E, Aguero EG, Silvestri GA, Sherman CA, Sharma AK. Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival. J Med Imaging Radiat Oncol. .54(5):483-9, 2010.
View in: PubMed

50.Fisher CS, Cole DJ, Mitas M, Garrett-Meyer E, Metcalf JS, Gillanders WE, Mikhitarian K, Urist MM, Mann GB, Doherty G, Herrmann VM, Hill AD, Eremin O, El-Sheemy M, Orr RK, Valle AA, Henderson MA, Dewitty RL, Sugg SL, Frykberg E, Yeh K, Bell RM, Baker MK. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes fails to predict breast cancer recurrence: a final analysis of a prospective multi-institutional cohort study. Ann Surg Oncol. .17 Suppl 3:312-20, 2010.
View in: PubMed

51.Ruppert BN, Watkins JM, Shirai K, Wahlquist AE, Garrett-Mayer E, Aguero EG, Sherman CA, Reed CE, Sharma AK. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol. .33(4):346-52, 2010.
View in: PubMed

52.Ford ME, Wahlquist AE, Ridgeway C, Streets J, Mitchum KA, Harper RR, Hamilton I, Etheredge JJ, Jefferson MS, Varner H, Campbell K, Garrett-Mayer E. Evaluating an intervention to increase cancer knowledge in racially diverse communities in South Carolina. Patient Educ Couns. .83(2):256-60, 2010. PMCID: PMC4146402
View in: PubMed

53.Watkins JM, Fortney JA, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Sherman CA, Turrisi AT, Sharma AK. Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol. .28(5):340-8, 2010.
View in: PubMed

54.Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. .16(6):1726-36, 2010.
View in: PubMed

55.Watkins JM, Zauls AJ, Wahlquist AH, Shirai K, Garrett-Mayer E, Gillespie MB, Day TA, Sharma AK. Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer. Laryngoscope. .120(2):236-42, 2010.
View in: PubMed

56.Bossaer JB, Hall PD, Garrett-Mayer E. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer. .19(2):231-7, 2010.
View in: PubMed

57.Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, Levitsky HI. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. .16(1):338-47, 2010. PMCID: PMC2804932
View in: PubMed

58.Cunningham JE, Montero AJ, Garrett-Mayer E, Berkel HJ, Ely B. Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control. .21(3):399-409, 2009.
View in: PubMed

59.Harper JL, Watkins JM, Zauls AJ, Wahlquist AE, Garrett-Mayer E, Baker MK, Cole DJ, Dragun AE, Jenrette JM. Six-year experience: long-term disease control outcomes for partial breast irradiation using MammoSite balloon brachytherapy. Am J Surg. .199(2):204-9, 2009.
View in: PubMed

60.Yang C, Garrett-Mayer E, Schneider JS, Gollomp SM, Tilley BC. Repeatable battery for assessment of neuropsychological status in early Parkinson's disease. Mov Disord. .24(10):1453-60, 2009. PMCID: PMC3915413
View in: PubMed

61.Loeb DM, Garrett-Mayer E, Hobbs RF, Prideaux AR, Sgouros G, Shokek O, Wharam MD, Scott T, Schwartz CL. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. .115(11):2514-22, 2009. PMCID: PMC2974628
View in: PubMed

62.Carpenter MJ, Garrett-Mayer E, Vitoc C, Cartmell K, Biggers S, Alberg AJ. Adolescent nondaily smokers: favorable views of tobacco yet receptive to cessation. Nicotine Tob Res. .11(4):348-55, 2009. PMCID: PMC2670369
View in: PubMed

63.Watkins JM, Shirai KS, Wahlquist AE, Stuart RK, Chaudhary UB, Garrett-Mayer E, Day TA, Gillespie MB, Sharma AK. Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck. .31(4):493-502, 2009.
View in: PubMed

64.Zellars RC, Stearns V, Frassica D, Asrari F, Tsangaris T, Myers L, DiPasquale S, Lange JR, Jacobs LK, Emens LA, Armstrong DK, Fetting JH, Garrett-Mayer E, Davidson NE, Wolff AC. Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. J Clin Oncol. .27(17):2816-22, 2009.
View in: PubMed

65.Nonemaker JM, Garrett-Mayer E, Carpenter MJ, Ford ME, Silvestri G, Lackland DT, Alberg AJ. The risk of dying from lung cancer by race: a prospective cohort study in a biracial cohort in Charleston, South Carolina. Ann Epidemiol. .19(5):304-10, 2009.
View in: PubMed

66.Watkins JM, Marshall DT, Patel S, Giglio P, Herrin AE, Garrett-Mayer E, Jenrette JM. High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas. J Neurooncol. .93(3):343-8, 2009.
View in: PubMed

67.Nietert PJ, Ravenel JG, Leue WM, Miller JV, Taylor KK, Garrett-Mayer ES, Silvestri GA. Imprecision in automated volume measurements of pulmonary nodules and its effect on the level of uncertainty in volume doubling time estimation. Chest. .135(6):1580-7, 2009.
View in: PubMed

68.Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith BD, Ironside V, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei AA, Gore SD, Levis MJ, Wright JJ, Garrett-Mayer E, Kaufmann SH. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. .113(20):4841-52, 2008. PMCID: PMC2686135
View in: PubMed

69.Watkins JM, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Fortney JA, Sherman CA, Sharma AK. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. .74(4):1108-13, 2008.
View in: PubMed

70.Hall PD, Beagle KL, Garrett-Mayer E, Frankel AE. Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein. Anticancer Drugs. .19(10):1007-11, 2008.
View in: PubMed

71.Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. .26(25):4172-9, 2008. PMCID: PMC2654371
View in: PubMed

72.Blum C, Graham A, Yousefzadeh M, Shrout J, Benjamin K, Krishna M, Hoda R, Hoda R, Cole DJ, Garrett-Mayer E, Reed C, Wallace M, Mitas M. The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. Int J Oncol. .33(3):579-84, 2008. PMCID: PMC3399116
View in: PubMed

73.Su SC, Caffo B, Garrett-Mayer E, Bassett SS. Modified test statistics by inter-voxel variance shrinkage with an application to f MRI. Biostatistics. .10(2):219-27, 2008. PMCID: PMC3159431
View in: PubMed

74.McRackan TR, Watkins JM, Herrin AE, Garrett-Mayer EM, Sharma AK, Day TA, Gillespie MB. Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope. .118(7):1180-5, 2008.
View in: PubMed

75.Moussa O, Ashton AW, Fraig M, Garrett-Mayer E, Ghoneim MA, Halushka PV, Watson DK. Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. Cancer Res. .68(11):4097-104, 2008.
View in: PubMed

76.Shrout J, Yousefzadeh M, Dodd A, Kirven K, Blum C, Graham A, Benjamin K, Hoda R, Krishna M, Romano M, Wallace M, Garrett-Mayer E, Mitas M. beta(2)microglobulin mRNA expression levels are prognostic for lymph node metastasis in colorectal cancer patients. Br J Cancer. .98(12):1999-2005, 2008. PMCID: PMC2441949
View in: PubMed

77.Snyder CF, Garrett-Mayer E, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW. Symptoms, supportive care needs, and function in cancer patients: how are they related? Qual Life Res. .17(5):665-77, 2008. PMCID: PMC3072840
View in: PubMed

78.Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris L, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res. .14(10):3077-82, 2008. PMCID: PMC3074480
View in: PubMed

79.Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. .58(1):49-59, 2008. PMCID: PMC3401888
View in: PubMed

80.Alumkal JJ, Zhang Z, Humphreys EB, Bennett C, Mangold LA, Carducci MA, Partin AW, Garrett-Mayer E, DeMarzo AM, Herman JG. Effect of DNA methylation on identification of aggressive prostate cancer. Urology. .72(6):1234-9, 2008. PMCID: PMC2874954
View in: PubMed

81.Klassen AC, Garrett-Mayer E, Houts PS, Shankar S, Torio CM. The relationship of body size to participation and success in a fruits and vegetables intervention among low-income women. J Community Health. .33(2):78-89, 2008.
View in: PubMed

82.Warlick ED, O'Donnell PV, Borowitz M, Grupka N, Decloe L, Garrett-Mayer E, Borrello I, Brodsky R, Fuchs E, Huff CA, Luznik L, Matsui W, Ambinder R, Jones RJ, Smith BD. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res. .32(9):1439-47, 2008. PMCID: PMC2719785
View in: PubMed

83.Reed CE, Graham A, Hoda RS, Khoor A, Garrett-Mayer E, Wallace MB, Mitas M. A simple two-gene prognostic model for adenocarcinoma of the lung. J Thorac Cardiovasc Surg. .135(3):627-34, 2008. PMCID: PMC2774741
View in: PubMed

84.Hooker AC, Ten Tije AJ, Carducci MA, Weber J, Garrett-Mayer E, Gelderblom H, McGuire WP, Verweij J, Karlsson MO, Baker SD. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin Pharmacol Ther. .84(1):111-8, 2008. PMCID: PMC3092481
View in: PubMed

85.Choti MA, Kaloma F, de Oliveira ML, Nour S, Garrett-Mayer ES, Sheth S, Pawlik TM. Patient variability in intraoperative ultrasonographic characteristics of colorectal liver metastases. Arch Surg. .143(1):29-34; discussion 35, 2008.
View in: PubMed

86.Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, Hoque MO, Chang S, Brait M, Nayak CS, Jiang WW, Claybourne Q, Tokumaru Y, Lee J, Goldenberg D, Garrett-Mayer E, Goodman S, Moon CS, Koch W, Westra WH, Sidransky D, Califano JA. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res. .14(1):97-107, 2008.
View in: PubMed

87.Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C, Konishi Y, Blair BG, Brenner K, Garrett-Mayer E, Carraway H, Bachman KE, Park BH. Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci U S A. .105(1):288-93, 2007. PMCID: PMC2224203
View in: PubMed

88.Beldner MA, Sherman CA, Green MR, Garrett-Mayer E, Chaudhary U, Meyer ML, Kraft AS, Montero AJ. Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer. .7:231, 2007. PMCID: PMC2241632
View in: PubMed

89.Antonarakis ES, Blackford AL, Garrett-Mayer E, Eisenberger MA. Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol. .25(31):4998-5008, 2007. PMCID: PMC4133788
View in: PubMed

90.Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. .13(21):6396-403, 2007.
View in: PubMed

91.Garrett-Mayer E, Parmigiani G, Zhong X, Cope L, Gabrielson E. Cross-study validation and combined analysis of gene expression microarray data. Biostatistics. .9(2):333-54, 2007.
View in: PubMed

92.Koyfman SA, Agrawal M, Garrett-Mayer E, Krohmal B, Wolf E, Emanuel EJ, Gross CP. Risks and benefits associated with novel phase 1 oncology trial designs. Cancer. .110(5):1115-24, 2007.
View in: PubMed

93.Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, Eisenberger M. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. .25(25):3965-70, 2007.
View in: PubMed

94.Bolaños-Meade J, Garrett-Mayer E, Luznik L, Anders V, Webb J, Fuchs EJ, Huff CA, Matsui W, Borrello IM, Brodsky R, Kasamon YL, Swinnen LJ, Flinn IW, Ambinder RF, Jones RJ, Hess AD, Vogelsang GB. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant. .13(10):1185-91, 2007. PMCID: PMC2271148
View in: PubMed

95.Lee JS, Lo PK, Fackler MJ, Argani P, Zhang Z, Garrett-Meyer E, Sukumar S. A comparative study of Korean with Caucasian breast cancer reveals frequency of methylation in multiple genes correlates with breast cancer in young, ER, PR-negative breast cancer in Korean women. Cancer Biol Ther. .6(7):1114-20, 2007.
View in: PubMed

96.Jimeno A, Hallur G, Chan A, Zhang X, Cusatis G, Chan F, Shah P, Chen R, Hamel E, Garrett-Mayer E, Khan S, Hidalgo M. Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. Mol Cancer Ther. .6(5):1509-16, 2007.
View in: PubMed

97.Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. .177(5):1777-81, 2007.
View in: PubMed

98.Giuntoli RL, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. .106(1):82-8, 2007.
View in: PubMed

99.Cornblatt BS, Ye L, Dinkova-Kostova AT, Erb M, Fahey JW, Singh NK, Chen MS, Stierer T, Garrett-Mayer E, Argani P, Davidson NE, Talalay P, Kensler TW, Visvanathan K. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis. .28(7):1485-90, 2007.
View in: PubMed

100.Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst. .99(5):376-85, 2007. PMCID: PMC4133793
View in: PubMed

101.Shalowitz DI, Garrett-Mayer E, Wendler D. How should treatment decisions be made for incapacitated patients, and why? PLoS Med. .4(3):e35, 2007. PMCID: PMC1820603
View in: PubMed

102.Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA, DeWeese TL. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. .69(3):526-31, 2007.
View in: PubMed

103.Nilsson KR, Berenholtz SM, Garrett-Mayer E, Dorman T, Klag MJ, Pronovost PJ. Association between venous thromboembolism and perioperative allogeneic transfusion. Arch Surg. .142(2):126-32; discussion 133, 2007.
View in: PubMed

104.Sullivan M, Finelli J, Marvin A, Garrett-Mayer E, Bauman M, Landa R. Response to joint attention in toddlers at risk for autism spectrum disorder: a prospective study. J Autism Dev Disord. .37(1):37-48, 2007.
View in: PubMed

105.Hurst SA, Perrier A, Pegoraro R, Reiter-Theil S, Forde R, Slowther AM, Garrett-Mayer E, Danis M. Ethical difficulties in clinical practice: experiences of European doctors. J Med Ethics. .33(1):51-7, 2007. PMCID: PMC2598078
View in: PubMed

106.Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. .109(4):1387-94, 2006. PMCID: PMC1794070
View in: PubMed

107.Ulrich CM, Danis M, Ratcliffe SJ, Garrett-Mayer E, Koziol D, Soeken KL, Grady C. Ethical conflict in nurse practitioners and physician assistants in managed care. Nurs Res. .55(6):391-401, 2006.
View in: PubMed

108.Shankar S, Klassen AC, Garrett-Mayer E, Houts PS, Wang T, McCarthy M, Cain R, Zhang L. Evaluation of a nutrition education intervention for women residents of Washington, DC, public housing communities. Health Educ Res. .22(3):425-37, 2006.
View in: PubMed

109.Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. .12(9):965-72, 2006.
View in: PubMed

110.Fackler MJ, Malone K, Zhang Z, Schilling E, Garrett-Mayer E, Swift-Scanlan T, Lange J, Nayar R, Davidson NE, Khan SA, Sukumar S. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res. .12(11 Pt 1):3306-10, 2006.
View in: PubMed

111.Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA, Flinn IW, Ambinder RF, Borrello IM, Matsui WH, Vogelsang GB, Griffin CA, Luznik L, Jones RJ. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. .12(4):414-21, 2006.
View in: PubMed

112.Shalowitz DI, Garrett-Mayer E, Wendler D. The accuracy of surrogate decision makers: a systematic review. Arch Intern Med. .166(5):493-7, 2006.
View in: PubMed

113.Lo PK, Mehrotra J, D'Costa A, Fackler MJ, Garrett-Mayer E, Argani P, Sukumar S. Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer. Cancer Biol Ther. .5(3):281-6, 2006.
View in: PubMed

114.Ravi R, Fuchs EJ, Jain A, Pham V, Yoshimura K, Prouser T, Jalla S, Zhou X, Garrett-Mayer E, Kaufmann SH, Schulick RD, Pardoll DM, Bedi A. Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Res. .66(3):1730-9, 2006.
View in: PubMed

115.Murata S, Kominsky SL, Vali M, Zhang Z, Garrett-Mayer E, Korz D, Huso D, Baker SD, Barber J, Jaffee E, Reilly RT, Sukumar S. Ductal access for prevention and therapy of mammary tumors. Cancer Res. .66(2):638-45, 2006.
View in: PubMed

116.Garrett-Mayer E. The continual reassessment method for dose-finding studies: a tutorial. Clin Trials. .3(1):57-71, 2006.
View in: PubMed

117.Kasamon YL, Flinn IW, Grever MR, Diehl LF, Garrett-Mayer E, Goodman SN, Lucas MS, Byrd JC. Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clin Cancer Res. .11(23):8413-7, 2005.
View in: PubMed

118.Allen E, Piontek KB, Garrett-Mayer E, Garcia-Gonzalez M, Gorelick KL, Germino GG. Loss of polycystin-1 or polycystin-2 results in dysregulated apolipoprotein expression in murine tissues via alterations in nuclear hormone receptors. Hum Mol Genet. .15(1):11-21, 2005. PMCID: PMC1525254
View in: PubMed

119.Diaz LA, Cheong I, Foss CA, Zhang X, Peters BA, Agrawal N, Bettegowda C, Karim B, Liu G, Khan K, Huang X, Kohli M, Dang LH, Hwang P, Vogelstein A, Garrett-Mayer E, Kobrin B, Pomper M, Zhou S, Kinzler KW, Vogelstein B, Huso DL. Pharmacologic and toxicologic evaluation of C. novyi-NT spores. Toxicol Sci. .88(2):562-75, 2005.
View in: PubMed

120.Emens LA, Kennedy MJ, Fetting JH, Davidson NE, Garrett E, Armstrong DK. A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer. Breast Cancer Res Treat. .76(2):145-56, 2002.
View in: PubMed

121.Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, Piantadosi S, Garrett E, Geiman DE, Hubbard W, Offerhaus GJ, Hamilton SR. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med. .346(14):1054-9, 2002. PMCID: PMC2225537
View in: PubMed